Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

bloomberg.com - Stock Movers: Intel, ServiceNow, West Pharma
Stock Movers: Intel, ServiceNow, West Pharma
Bloomberg

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street. Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for…

seekingalpha.com - Edmund Ingham - BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy (BBIO)
BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy (BBIO)
Seeking Alpha

BridgeBio Pharma, Inc. has surged 130% since last year, now trading at a $14.4bn market cap, driven by optimism around its pipeline and ATTR-CM drug Attruby. Attruby posted $362m in 2025 sales but faces stiff competition from Pfizer and Alnylam…

marketbeat.com - HC Wainwright Predicts Urogen Pharma Q3 Earnings
HC Wainwright Predicts Urogen Pharma Q3 Earnings
MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends Urogen Pharma (NASDAQ:URGN - Free Report) - HC Wainwright issued their Q3 2027 earnings per share estimates for shares of Urogen Pharma in a report released on Thursday, April 23rd. HC…

marketbeat.com - Zurcher Kantonalbank Zurich Cantonalbank Acquires 219,479 Shares of Royalty Pharma PLC $RPRX
Zurcher Kantonalbank Zurich Cantonalbank Acquires 219,479 Shares of Royalty Pharma PLC $RPRX
MarketBeat

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 222.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor…

marketbeat.com - Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of 'Buy' from Analysts
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of 'Buy' from Analysts
MarketBeat

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) has received an average rating of 'Buy' from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the…

rediff.com - Rediff News - Stock markets dive 790 pts in early trade
Stock markets dive 790 pts in early trade
Rediff.com

Benchmark indices Sensex and Nifty tumbled in early trade on Friday as surging oil prices and unabated foreign fund outflows unnerved investors. Weakness in IT stocks and a negative trend in global markets also weighed on investor sentiment. The…

rediff.com - Nandita Malik - Indian Stock Market Plunge: Oil Prices, FII Outflows & Geopolitical Tensions Drive Sell-off
Indian Stock Market Plunge: Oil Prices, FII Outflows & Geopolitical Tensions Drive Sell-off
Rediff.com

Indian benchmark indices Sensex and Nifty plummeted in early trade, reflecting investor anxiety over surging global oil prices, sustained foreign fund outflows, and ongoing geopolitical tensions in West Asia. Benchmark indices Sensex and Nifty…

rediff.com - Nandita Malik - Indian Stock Market Slumps: Sensex Drops 1000 Pts on Oil Price Rally, IT Sector Weakness
Indian Stock Market Slumps: Sensex Drops 1000 Pts on Oil Price Rally, IT Sector Weakness
Rediff.com

Indian equity markets experienced a significant downturn for the third consecutive day, with the Sensex plummeting nearly 1,000 points, as surging crude oil prices, substantial selling in the IT sector, and ongoing geopolitical tensions weighed…

seekingalpha.com - Dulan Lokuwithana - Organon stock climbs amid buyout rumors (OGN:NYSE)
Organon stock climbs amid buyout rumors (OGN:NYSE)
Seeking Alpha

Organon (OGN) shares climbed ~30% in the premarket on Friday after media reports indicated that India's Sun Pharmaceutical Industries is moving ahead with its biggest-ever M&A deal by submitting a $13B binding offer for the U.S. drugmaker.

thehindubusinessline.com - Nifty Prediction Today - April 24, 2026: Nifty futures: Bears gaining traction
Nifty Prediction Today - April 24, 2026: Nifty futures: Bears gaining traction
BusinessLine

Nifty 50 began today's session lower at 24,101 compared to yesterday's close of 24,173. The index slipped further after opening and is now trading at 23,950, down 0.9 per cent so far today. The advance/decline ratio stands at 10/40, showing a…

cnbc.com - Michael Bloom - Here are Friday's biggest analyst calls: Apple, AMD, Intel, Oracle, Caterpillar, Shake Shack & more
Here are Friday's biggest analyst calls: Apple, AMD, Intel, Oracle, Caterpillar, Shake Shack & more
CNBC

Here are the biggest calls on Wall Street on Friday: Evercore ISI upgrades Intel to outperform from in line Evercore upgraded the stock following earnings on Thursday. 'Improved Execution: INTC's new CEO fixed the balance sheet, and is executing on…

thehindu.com - Pti - Stock markets tumble on surging oil prices, foreign fund outflows
Stock markets tumble on surging oil prices, foreign fund outflows
The Hindu

Benchmark indices Sensex and Nifty tumbled in early trade on Friday (April 24, 2026) as surging oil prices and unabated foreign fund outflows unnerved investors. Weakness in IT stocks and a negative trend in global markets also weighed on investor…

thehindubusinessline.com - The great un-bundling: How maturing Indian markets are shrugging off concentration
The great un-bundling: How maturing Indian markets are shrugging off concentration
BusinessLine

The National Stock Exchange's latest Market Pulse report from April offers an interesting comparative study, benchmarking global markets and revealing the key structural shifts in Indian markets that are driving greater maturity and resilience.

cnbc.com - Annika Kim Constantino - Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
CNBC

Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump. The biotech company will also offer the first hearing-loss gene therapy for free to eligible U.S. patients following regulatory approval of…

salon.com - Craig R. McCoy - After years of waiting, many opioid victims will be shut out of Purdue settlement
After years of waiting, many opioid victims will be shut out of Purdue settlement
Salon.com

Mary Jannotta sliced meat and cheese behind deli counters at Acme and Pathmark supermarkets in the Philadelphia suburbs for decades, developing aches that came with working on her feet. A botched back surgery in 2008 made the pain worse. Her doctor…

Receive a Daily briefing on Pharma Industry News

Get Started